939 United Therapeutics Corporation $UTHR Shares Sold by Generali Asset Management SPA SGR

Generali Asset Management SPA SGR decreased its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 89.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 109 shares of the biotechnology company’s stock after selling 939 shares during the period. Generali Asset Management SPA SGR’s holdings in United Therapeutics were worth $59,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in United Therapeutics in the 2nd quarter valued at about $2,868,735,000. Janus Henderson Group PLC grew its stake in shares of United Therapeutics by 8.9% during the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after acquiring an additional 70,829 shares in the last quarter. Jupiter Topco LLC purchased a new stake in shares of United Therapeutics during the second quarter worth about $450,140,000. Swedbank AB increased its position in shares of United Therapeutics by 0.7% during the first quarter. Swedbank AB now owns 327,122 shares of the biotechnology company’s stock worth $193,977,000 after acquiring an additional 2,350 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of United Therapeutics during the second quarter worth about $159,522,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Price Performance

NASDAQ UTHR opened at $598.72 on Friday. United Therapeutics Corporation has a 12 month low of $430.02 and a 12 month high of $609.99. The company has a market capitalization of $25.68 billion, a price-to-earnings ratio of 21.42, a price-to-earnings-growth ratio of 4.30 and a beta of 0.49. The company’s fifty day moving average price is $527.10 and its two-hundred day moving average price is $530.54.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $6.41 EPS. As a group, analysts anticipate that United Therapeutics Corporation will post 26.09 EPS for the current year.

United Therapeutics announced that its board has authorized a stock repurchase program on Thursday, October 22nd that authorizes the company to repurchase $2 billion in shares. This buyback authorization authorizes the biotechnology company to buy up to 8.3% of its stock through open market purchases. Share buyback programs are typically an indication that the company’s management believes its shares are undervalued.

Analyst Ratings Changes

Several research analysts recently commented on the company. Leerink Partners boosted their price target on United Therapeutics from $685.00 to $725.00 and gave the stock an “outperform” rating in a research note on Monday, October 19th. JPMorgan Chase & Co. lowered their price objective on United Therapeutics from $710.00 to $695.00 and set an “overweight” rating for the company in a research note on Wednesday. Morgan Stanley raised their price objective on United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 7th. Raymond James Financial restated an “outperform” rating and set a $717.00 price objective on shares of United Therapeutics in a report on Tuesday, October 20th. Finally, UBS Group set a $725.00 target price on United Therapeutics in a research report on Monday, October 19th. Twelve investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $667.07.

Insider Activity

In other news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $544.30, for a total value of $4,517,690.00. Following the completion of the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $24,587,119.60. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Wednesday, October 28th. The shares were sold at an average price of $585.49, for a total value of $5,562,155.00. Following the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $189,958,132.07. This represents a 2.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 401,528 shares of company stock worth $210,097,491. 8.60% of the stock is owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.